Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7734299 | 0.81 | SLC6A3 (0.42) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL13332854 | 0.81 | SLC6A3 (0.46) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL10157188 | 0.77 | SLC6A3 (0.39) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL8362857 | 0.75 | SLC6A3 (0.37) | SLC6A3SLC6A4SLC6A2MMP1MMP13 | |
| SCHEMBL19368144 | 0.73 | ALDH1A1 (0.43) | SLC6A3SLC6A4SLC6A2OPRM1 | |
| SCHEMBL27811583 | 0.66 | SLC6A3 (0.37) | SLC6A3SLC6A4SLC6A2OPRM1 | |
| SCHEMBL13932847 | 0.66 | MAOB (0.41) | SLC6A3SLC6A2 | |
| SCHEMBL10181623 | 0.65 | OPRM1 (0.40) | SLC6A3SLC6A4SLC6A2OPRM1 | |
| SCHEMBL871577 | 0.65 | CYP3A4 (0.70) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL25136197 | 0.65 | MAOA (0.41) | SLC6A3SLC6A4SLC6A2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759337-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8426595-B2 | Gamma secretase modulators | MERCK SHARP & DOHME LLC | 2013-04-23 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-05-31 | — | — | US | disclosed |
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-01 | — | — | US | disclosed |
| US-20110257163-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-10-20 | — | — | US | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4483/4885SLC6A4 4475/4885SLC6A2 4451/4885 |
| US-20110294784-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | SLC6A3 4148/4885SLC6A4 4205/4885SLC6A2 3854/4885 |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4483/4885SLC6A4 4475/4885SLC6A2 4451/4885 |
| US-20100297128-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4268/4885SLC6A4 4304/4885SLC6A2 3901/4885 |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4521/4885SLC6A4 4547/4885SLC6A2 4438/4885 |
| US-20120135980-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | SLC6A3 4148/4885SLC6A4 4205/4885SLC6A2 3854/4885 |
| US-20110257163-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4556/4885SLC6A4 4514/4885SLC6A2 4496/4885 |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4521/4885SLC6A4 4547/4885SLC6A2 4438/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | SLC6A3 4005/4885SLC6A4 4006/4885SLC6A2 3915/4885 |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | SLC6A3 4482/4885SLC6A4 4516/4885SLC6A2 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.